Evidence map›Paper›PMID 34431196›Full record

Trial reportHIV medicine2022

Effect of an opt-out point-of-care HIV-1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomized controlled trial.

Eduard J Sanders, Clara Agutu, Elise van der Elst, Amin Hassan, Evanson Gichuru, Peter Mugo, Carey Farquhar, Joseph B Babigumira, Steven M Goodreau, Deven T Hamilton and 4 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03508908 (Impact of a Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent HIV Infection and Reduce HIV Transmission - Tambua Mapema Plus), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03508908 nacompletednot on this map

Impact of a Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent HIV Infection and Reduce HIV Transmission - Tambua Mapema Plus

TypeinterventionalSponsorUniversity of OxfordRan2017 to 2022Enrolled2,887ConditionsHIV InfectionsArmsHIV-1 RNA testing
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Eduard J SandersKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.ORCID 0000-0002-1062-8921
Clara AgutuKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.
Elise van der ElstKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.
Amin HassanKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.
Evanson GichuruKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.
Peter MugoKEMRI - Wellcome Trust Research Programme, Kilifi, Kenya.
Carey FarquharDepartment of Medicine, Global Health, and Epidemiology, University of Washington, Seattle, WA, USA.
Joseph B BabigumiraDepartment of Global Health and Pharmacy, University of Washington, Seattle, WA, USA.
Steven M GoodreauDepartment of Anthropology and Epidemiology, University of Washington, Seattle, WA, USA.
Deven T HamiltonCenter for Studies in Demography & Ecology, University of Washington, Seattle, WA, USA.
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.
Martin SirengoNational AIDS & STI Control Programme, Nairobi, Kenya.
Wairimu ChegeNational Institutes of Allergy & Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Susan M GrahamUniversity of Oxford, Headington, UK.
Kenya Medical Research Institute · KEUniversity of Washington · USAfrica Health Research Institute · ZANational Aids Control Council · KENational Institutes of Health · US

Funding

Scientific/Technical CoreP2CHD042828 · NICHD · UNIVERSITY OF WASHINGTON · PI SARA R. CURRAN · 2017 to 2026
$6.3M
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)P30MH123248 · NIMH · UNIVERSITY OF WASHINGTON · PI SIMONI, JANE M. · 2021 to 2024
$5.8M
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmissionR01AI124968 · NIAID · UNIVERSITY OF WASHINGTON · PI GRAHAM, SUSAN MARIE, SANDERS, EDUARD · 2016 to 2019
$2.3M
NIAID NIH HHS R01 AI124968NICHD NIH HHS P2C HD042828NIMH NIH HHS P30 MH123248Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundIn sub-Saharan Africa, adult outpatients with symptoms of acute infectious illness are not routinely tested for prevalent or acute HIV infection (AHI) when seeking healthcare.

methodsAdult symptomatic outpatients aged 18-39 years were evaluated by a consensus AHI risk score. Patients with a risk score ≥ 2 and no previous HIV diagnosis were enrolled in a stepped-wedge trial of opt-out delivery of point-of-care (POC) HIV-1 nucleic acid testing (NAAT), compared with standard provider-initiated HIV testing using rapid tests in the observation period. The primary outcome was the number of new diagnoses in each study period. Generalized estimating equations with a log-binomial link and robust variance estimates were used to account for clustering by health facility. The trial is registered with ClinicalTrials.gov NCT03508908.

resultsBetween 2017 and 2020, 13 (0.9%) out of 1374 participants in the observation period and 37 (2.5%) out of 1500 participants in the intervention period were diagnosed with HIV infection. Of the 37 newly diagnosed cases in the intervention period, two (5.4%) had AHI. Participants in the opt-out intervention had a two-fold greater odds of being diagnosed with HIV (odds ratio = 2.2, 95% confidence interval: 1.39-3.51) after adjustment for factors imbalanced across study periods.

conclusionsAmong symptomatic adults aged 18-39 years targeted by our POC NAAT intervention, we identified one chronic HIV infection for every 40 patients and one AHI patient for every 750 patients tested. Although AHI yield was low in this population, routinely offered opt-out testing could diagnose twice as many patients as an approach relying on provider discretion.

Indexed as

HIV-1HIV InfectionsNucleic AcidsAdolescentAdultHumansKenyaOutpatientsPoint-of-Care SystemsYoung AdultNucleic Acidsacute HIV infectiondiagnostic testsHIV infectionpartner notificationpoint of careserologyviral load

Identifiers

PMID34431196
PMCPMC9204714
OpenAlexW3195696871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.